Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs

Bibliography

• Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med 2012;4(165):165rv13
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20(1):133-63
   PubMed Web of Science ®Google Scholar
• Calderone RA. Candida and candidiasis. ASM Press, Washington; 2002
   Google Scholar
• Lopez-Martinez R. Candidosis, a new challenge. Clin Dermatol 2010;28(2):178-84
   PubMed Web of Science ®Google Scholar
• Redding SW, Zellars RC, Kirkpatrick WR, et al. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol 1999;37(12):3896-900
   PubMed Web of Science ®Google Scholar
• Thompson GR III, Patel PK, Kirkpatrick WR, et al. Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109(4):488-95
   PubMed Web of Science ®Google Scholar
• Fidel PL Jr. Vaginal candidiasis: review and role of local mucosal immunity. AIDS Patient Care STDS 1998;12(5):359-66
   PubMed Web of Science ®Google Scholar
• Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29(2):239-44
   PubMed Web of Science ®Google Scholar
• Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37(9):1172-7
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48(5):503-35
   PubMed Web of Science ®Google Scholar
• Pittet D, Li N, Woolson RF, et al. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis 1997;24(6):1068-78
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41(9):1232-9
   PubMed Web of Science ®Google Scholar
• Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002;5(1):26-34
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Casadevall A, Galgiani JN, et al. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010;9(9):719-27
   PubMed Web of Science ®Google Scholar
• Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003;11(6):272-9
   PubMed Web of Science ®Google Scholar
• Perea S, Lopez-Ribot JL, Kirkpatrick WR, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001;45(10):2676-84
   PubMed Web of Science ®Google Scholar
• Kuhn DM, Ghannoum MA. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 2004;5(2):186-97
   PubMedGoogle Scholar
• Ramage G, Vande Walle K, Wickes BL, et al. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001;45(9):2475-9
   PubMed Web of Science ®Google Scholar
• Hernandez S, Lopez-Ribot JL, Najvar LK, et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004;48(4):1382-3
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Grabinski JL, Garcia-Effron G, et al. Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob Agents Chemother 2008;52(11):4145-8
   PubMed Web of Science ®Google Scholar
• Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 2007;3(9):541-8
   PubMed Web of Science ®Google Scholar
• Gauwerky K, Borelli C, Korting HC. Targeting virulence: a new paradigm for antifungals. Drug Discov Today 2009;14(3-4):214-22
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 2003;1(1):17-24
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. Microbial virulence results from the interaction between host and microorganism. Trends Microbiol 2003;11(4):157-8; author reply 58-9
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski L. Host-pathogen interactions: the attributes of virulence. J Infect Dis 2001;184(3):337-44; Epub 2001 Jun 27
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. Host-pathogen interactions: basic concepts of microbial commensalism, colonization, infection, and disease. Infect Immun 2000;68(12):6511-18
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. What is a pathogen? Ann Med 2002;34(1):2-4
   PubMed Web of Science ®Google Scholar
• Calderone RA, Cihlar RL. Fungal pathogenesis. Principles and Clinical Applications. Marcel Decker, New York; 2002
   Google Scholar
• Calderone RA, Fonzi WA. Virulence factors of Candida albicans. Trends Microbiol 2001;9(7):327-35
   PubMed Web of Science ®Google Scholar
• Davis D. Adaptation to environmental pH in Candida albicans and its relation to pathogenesis. Curr Genet 2003;44(1):1-7; Epub 2003 Jun 18
   PubMed Web of Science ®Google Scholar
• Soll DR. Candida commensalism and virulence: the evolution of phenotypic plasticity. Acta Trop 2002;81(2):101-10
   PubMed Web of Science ®Google Scholar
• Chaffin WL, Lopez-Ribot JL, Casanova M, et al. Cell wall and secreted proteins of Candida albicans: identification, function, and expression. Microbiol Mol Biol Rev 1998;62(1):130-80
   PubMed Web of Science ®Google Scholar
• Cutler JE. Putative virulence factors of Candida albicans. Annu Rev Microbiol 1991;45:187-218
   PubMed Web of Science ®Google Scholar
• Odds FC, Gow NA, Brown AJ. Fungal virulence studies come of age. Genome Biol 2001;2:1009.1-4
   Web of Science ®Google Scholar
• Sudbery PE. Growth of Candida albicans hyphae. Nat Rev Microbiol 2011;9(10):737-48
   PubMed Web of Science ®Google Scholar
• Banerjee M, Thompson DS, Lazzell A, et al. UME6, a novel filament-specific regulator of Candida albicans hyphal extension and virulence. Mol Biol Cell 2008;19(4):1354-65
   PubMed Web of Science ®Google Scholar
• Braun BR, Johnson AD. Control of filament formation in Candida albicans by the transcriptional repressor TUP1. Science 1997;277(5322):105-9
   PubMed Web of Science ®Google Scholar
• Braun BR, Johnson AD. TUP1, CPH1 and EFG1 make independent contributions to filamentation in Candida albicans. Genetics 2000;155(1):57-67
   PubMed Web of Science ®Google Scholar
• Braun BR, Kadosh D, Johnson AD. NRG1, a repressor of filamentous growth in C.albicans, is down-regulated during filament induction. Embo J 2001;20(17):4753-61
   PubMed Web of Science ®Google Scholar
• Carlisle PL, Banerjee M, Lazzell A, et al. Expression levels of a filament-specific transcriptional regulator are sufficient to determine Candida albicans morphology and virulence. Proc Natl Acad Sci USA 2009;106(2):599-604
   PubMed Web of Science ®Google Scholar
• Ernst JF. Transcription factors in Candida albicans - environmental control of morphogenesis. Microbiology 2000;146(Pt 8):1763-74
   PubMedGoogle Scholar
• Murad AM, Leng P, Straffon M, et al. NRG1 represses yeast-hypha morphogenesis and hypha-specific gene expression in Candida albicans. Embo J 2001;20(17):4742-52
   PubMed Web of Science ®Google Scholar
• Saville SP, Lazzell AL, Monteagudo C, et al. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell 2003;2(5):1053-60
   PubMed Web of Science ®Google Scholar
• Zheng X, Wang Y. Hgc1, a novel hypha-specific G1 cyclin-related protein regulates Candida albicans hyphal morphogenesis. Embo J 2004;23(8):1845-56
   PubMed Web of Science ®Google Scholar
• MacCallum DM, Odds FC. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 2005;48(3):151-61
   PubMed Web of Science ®Google Scholar
• Phan QT, Belanger PH, Filler SG. Role of hyphal formation in interactions of Candida albicans with endothelial cells. Infect Immun 2000;68(6):3485-90
   PubMed Web of Science ®Google Scholar
• Lo HJ, Kohler JR, DiDomenico B, et al. Nonfilamentous C. albicans mutants are avirulent. Cell 1997;90(5):939-49
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Lazzell AL, Saville SP, et al. Validation of the tetracycline regulatable gene expression system for the study of the pathogenesis of infectious disease. PLoS One 2011;6(5):e20449
   PubMed Web of Science ®Google Scholar
• Nakayama H, Mio T, Nagahashi S, et al. Tetracycline-regulatable system to tightly control gene expression in the pathogenic fungus Candida albicans. Infect Immun 2000;68(12):6712-19
   PubMed Web of Science ®Google Scholar
• Saville SP, Lazzell AL, Bryant AP, et al. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob Agents Chemother 2006;50(10):3312-16
   PubMed Web of Science ®Google Scholar
• Chang W, Li Y, Zhang L, et al. Retigeric acid B attenuates the virulence of Candida albicans via inhibiting adenylyl cyclase activity targeted by enhanced farnesol production. PLoS ONE 2012;7(7):e41624
   PubMed Web of Science ®Google Scholar
• Gibson J, Sood A, Hogan DA. Pseudomonas aeruginosa-Candida albicans interactions: localization and fungal toxicity of a phenazine derivative. Appl Environ Microbiol 2009;75(2):504-13
   PubMed Web of Science ®Google Scholar
• Hogan DA, Vik A, Kolter R. A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol Microbiol 2004;54(5):1212-23
   PubMed Web of Science ®Google Scholar
• Hornby JM, Jensen EC, Lisec AD, et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 2001;67(7):2982-92
   PubMed Web of Science ®Google Scholar
• Joyner PM, Liu J, Zhang Z, et al. Mutanobactin A from the human oral pathogen Streptococcus mutans is a cross-kingdom regulator of the yeast-mycelium transition. Org Biomol Chem 2010;8(24):5486-9
   PubMed Web of Science ®Google Scholar
• Martins M, Henriques M, Azeredo J, et al. Morphogenesis control in Candida albicans and Candida dubliniensis through signaling molecules produced by planktonic and biofilm cells. Eukaryot Cell 2007;6(12):2429-36
   PubMed Web of Science ®Google Scholar
• Murzyn A, Krasowska A, Stefanowicz P, et al. Capric acid secreted by S. boulardii inhibits C. albicans filamentous growth, adhesion and biofilm formation. PLoS One 2010;5(8):e12050
   PubMed Web of Science ®Google Scholar
• Zhang L, Chang W, Sun B, et al. Bisbibenzyls, a new type of antifungal agent, inhibit morphogenesis switch and biofilm formation through upregulation of DPP3 in Candida albicans. PLoS ONE 2011;6(12):e28953
   PubMed Web of Science ®Google Scholar
• Midkiff J, Borochoff-Porte N, White D, et al. Small molecule inhibitors of the Candida albicans budded-to-hyphal transition act through multiple signaling pathways. PLoS One 2011;6(9):e25395
   PubMed Web of Science ®Google Scholar
• Toenjes KA, Munsee SM, Ibrahim AS, et al. Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrob Agents Chemother 2005;49(3):963-72
   PubMed Web of Science ®Google Scholar
• Shareck J, Belhumeur P. Modulation of morphogenesis in Candida albicans by various small molecules. Eukaryot Cell 2011;3:3
   Google Scholar
• Navarathna DH, Hornby JM, Krishnan N, et al. Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans. Infect Immun 2007;75(4):1609-18
   PubMed Web of Science ®Google Scholar
• Martins M, Lazzell AL, Lopez-Ribot JL, et al. Effect of exogenous administration of Candida albicans autoregulatory alcohols in a murine model of hematogenously disseminated candidiasis. J Basic Microbiol 2012;52(4):487-91
   PubMed Web of Science ®Google Scholar
• Cheng SC, Joosten LA, Kullberg BJ, et al. Interplay between Candida albicans and the mammalian innate host defense. Infect Immun 2012;80(4):1304-13
   PubMed Web of Science ®Google Scholar
• Netea MG, Brown GD, Kullberg BJ, et al. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 2008;6(1):67-78
   PubMed Web of Science ®Google Scholar
• Fidel PL Jr, Barousse M, Espinosa T, et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 2004;72(5):2939-46
   PubMed Web of Science ®Google Scholar
• Moyes DL, Runglall M, Murciano C, et al. A biphasic innate immune MAPK response discriminates between the yeast and hyphal forms of Candida albicans in epithelial cells. Cell Host Microbe 2010;8(3):225-35
   PubMed Web of Science ®Google Scholar
• Lorenz MC, Fink GR. The glyoxylate cycle is required for fungal virulence. Nature 2001;412(6842):83-6
   PubMed Web of Science ®Google Scholar
• MacCallum DM, Castillo L, Brown AJ, et al. Early-expressed chemokines predict kidney immunopathology in experimental disseminated Candida albicans infections. PLoS One 2009;4(7):e6420
   PubMed Web of Science ®Google Scholar
• Costerton JW, Cheng KJ, Geesey GG, et al. Bacterial biofilms in nature and disease. Annu Rev Microbiol 1987;41:435-64
   PubMed Web of Science ®Google Scholar
• Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis 2002;8(9):881-90
   PubMed Web of Science ®Google Scholar
• Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284(5418):1318-22
   PubMed Web of Science ®Google Scholar
• Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004;350(14):1422-9
   PubMed Web of Science ®Google Scholar
• Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15(2):167-93
   PubMed Web of Science ®Google Scholar
• Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004;17(2):255-67
   PubMed Web of Science ®Google Scholar
• Nett J, Andes D. Candida albicans biofilm development, modeling a host-pathogen interaction. Curr Opin Microbiol 2006;9(4):340-5
   PubMed Web of Science ®Google Scholar
• Ramage G, Martinez JP, Lopez-Ribot JL. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res 2006;6(7):979-86
   PubMed Web of Science ®Google Scholar
• Ramage G, Mowat E, Jones B, et al. Our current understanding of fungal biofilms. Crit Rev Microbiol 2009;35(4):340-55
   PubMed Web of Science ®Google Scholar
• Ramage G, Saville SP, Thomas DP, et al. Candida biofilms: an update. Eukaryot Cell 2005;4(4):633-8
   PubMed Web of Science ®Google Scholar
• Crump JA, Collignon PJ. Intravascular catheter-associated infections. Eur J Clin Microbiol Infect Dis 2000;19(1):1-8
   PubMed Web of Science ®Google Scholar
• Raad I. Intravascular-catheter-related infections. Lancet 1998;351(9106):893-8
   PubMed Web of Science ®Google Scholar
• Viudes A, Peman J, Canton E, et al. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 2002;21(11):767-74
   PubMed Web of Science ®Google Scholar
• Chandra J, Kuhn DM, Mukherjee PK, et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001;183(18):5385-94
   PubMed Web of Science ®Google Scholar
• Nobile CJ, Mitchell AP. Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 2006;8(9):1382-91
   PubMed Web of Science ®Google Scholar
• Uppuluri P, Chaturvedi AK, Srinivasan A, et al. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog 2010;6(3):e1000828
   PubMed Web of Science ®Google Scholar
• Ramage G, Saville SP, Wickes BL, et al. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002;68(11):5459-63
   PubMed Web of Science ®Google Scholar
• Ramage G, VandeWalle K, Lopez-Ribot JL, et al. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett 2002;214(1):95-100
   PubMed Web of Science ®Google Scholar
• Lopez-Ribot JL. Candida albicans biofilms: more than filamentation. Curr Biol 2005;15(12):R453-5
   PubMed Web of Science ®Google Scholar
• Nobile CJ, Fox EP, Nett JE, et al. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 2012;148(1-2):126-38
   PubMed Web of Science ®Google Scholar
• Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother 2008;62(1):153-5
   PubMed Web of Science ®Google Scholar
• Redding S, Bhatt B, Rawls HR, et al. Inhibition of Candida albicans biofilm formation on denture material. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107(5):669-72
   PubMed Web of Science ®Google Scholar
• Pierce CG, Uppuluri P, Tristan AR, et al. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc 2008;3(9):1494-500
   PubMed Web of Science ®Google Scholar
• Robbins N, Uppuluri P, Nett J, et al. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog 2011;7(9):e1002257
   PubMed Web of Science ®Google Scholar
• Uppuluri P, Nett J, Heitman J, et al. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 2008;52(3):1127-32
   PubMed Web of Science ®Google Scholar
• Sardi JC, Scorzoni L, Bernardi T, et al. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 2013;62(Pt 1):10-24
   PubMed Web of Science ®Google Scholar
• LaFleur MD, Lucumi E, Napper AD, et al. Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms. J Antimicrob Chemother 2011;66(4):820-6
   PubMed Web of Science ®Google Scholar
• Siles S, Srinivasan A, Pierce CP, et al. High-throughput screening of a collection of known pharmacologically active small compounds for the identification of Candida albicans biofilm inhibitors. Antimicrob Agents Chemother 2013; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Martins M, Henriques M, Lopez-Ribot JL, et al. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses 2012;55(1):80-5
   PubMed Web of Science ®Google Scholar
• Martins M, Uppuluri P, Thomas DP, et al. Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms. Mycopathologia 2010;169(5):323-31
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Uppuluri P, Lopez-Ribot J, et al. Development of a High-Throughput Candida albicans Biofilm Chip. PLoS ONE 2011;6(4):e19036
   PubMed Web of Science ®Google Scholar
• Braun BR, van Het Hoog M, d'Enfert C, et al. A human-curated annotation of the Candida albicans genome. PLoS Genet 2005;1(1):36-57
   PubMed Web of Science ®Google Scholar
• Saville SP, Thomas DP, Lopez-Ribot JL. Use of genome information for the study of the pathogenesis of fungal infections and the development of diagnostic tools. Rev Iberoam Micol 2005;22(4):238-41
   PubMedGoogle Scholar
• Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003;51(3):513-21
   PubMed Web of Science ®Google Scholar